Association between elevated left ventricular mass index and increased cardiovascular events in patients with acute coronary syndrome: A sub-analysis of the HIJ-PROPER study.
acute coronary syndrome
cardiovascular events
left ventricular mass index
Journal
Echocardiography (Mount Kisco, N.Y.)
ISSN: 1540-8175
Titre abrégé: Echocardiography
Pays: United States
ID NLM: 8511187
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
05
07
2021
received:
07
05
2021
accepted:
19
07
2021
pubmed:
5
8
2021
medline:
15
12
2021
entrez:
4
8
2021
Statut:
ppublish
Résumé
This study aimed to assess the association between left ventricular mass index (LVMI) and cardiovascular events in patients with acute coronary syndrome (ACS) under standard ACS management. This study is the sub-analysis of the HIJ-PROPER study. A total of 299 patients who had echocardiographic LVMI data were included in the current analysis. The participants were divided into four groups according to the LVMI quartile [quartile 1 (Q1), 77 (25.8%); quartile 2 (Q2), 73 (24.4%); quartile 3 (Q3), 74 (24.7%); and quartile 4 (Q4), 75 (25.1%)]. The incidence of cardiovascular events was compared among the four groups. The primary endpoint was defined as the composite endpoint of all-cause death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for heart failure. Mean LVMI in the four groups was 68.1±8.6, 86.2±3.8, 101.1±4.9, and 126.0±18.5 g/m Elevated LVMI was associated with increased cardiovascular events in patients with ACS under standard management. Adequately powered studies are warranted to validate these findings.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1567-1573Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Levy D, Gerrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
Ghali JK, Liao Y, Simmons B, et al. The 30 prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 1992;117:831-836.
Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-586.
Verdecchia P, Carini G, Circo A, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001;38:1829-1835.
Verma A, Meris A, Skali H, et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging. 2008;1:582-591.
Westerhout CM, Lauer MS, James S, et al. Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women. Eur Heart J. 2007;28:2064-2069.
Nepper-Christensen L, Lønborg J, Ahtarovski KA, et al. Left ventricular hypertrophy is associated with increased infarct size and decreased myocardial salvage in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Am Heart Assoc. 2017;6:e004823.
Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-2619.
Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J. 2017;38:2264-2276.
Kawada-Watanabe E, Ogawa H, Koyanagi R, et al. Rationale, design feature, and baseline characteristics: the HIJ-PROPER. J Cardiol. 2017;69:536-541.
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.
Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358:1370-1380.
Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21:500-506.
Levy D, Anderson KM, Savage DD, et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J of Cardiol. 1987;60:560-565.
Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998;32:1454-1459.
Kannel WB, Dauenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol. 1987;60:851-931.
Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
Mensah GA, Pappas TW, Koren MJ, et al. Comparison of classification of hypertension severity by blood pressure level and World Health Organization criteria for prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens. 1993;11:1429-1440.
Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995;13:1091-1095.
Liao Y, Cooper RS, Mensah GA, et al. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation. 1995;92:805-810.
Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334-341.
Barbieri A, Bursi F, Mantovani F, et al. Prognostic impact of left ventricular mass severity according to the classification proposed by the American Society of Echocardiography/European Association of Echocardiography. J Am Soc Echocardiogr. 2011;24:1383-1391.
Abdi-Ali A, Miller RJH, Southern D, et al. LV mass independently predicts mortality and need for future revascularization in patients undergoing diagnostic coronary angiography. JACC Cardiovasc Imaging. 2018;11:423-433.
Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart. 2005;91:250-256.
Lund BP, Gohlke-Bärwolf C, Cramariuc D, et al. Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy). Am J Cardiol. 2010;105:1456-1460.
Lazzeroni D, Rimoldi O, Gamici PG. From left ventricular hypertrophy to dysfunction and failure. Circ J. 2016;80:555-564.
Yilmaz A, Sechtem U. Diagnostic approach and differential diagnosis in patients with hypertrophied left ventricles. Heart. 2014;100:662-671.